GENE THERAPY FOR EYE PATHOLOGIES

Compositions and methods are described for the delivery of therapeutic products (such as therapeutic proteins (for example, antibodies), therapeutic RNAs (for example, shRNAs, siRNAs, and miRNAs), and therapeutic aptamers) to the retina/vitreal humour in the eyes of human subjects to treat pathologi...

Full description

Saved in:
Bibliographic Details
Main Authors DANOS Olivier, VAN EVEREN Sherri, CURTISS Darin Thomas, PATEL Samir Maganbhai, GHANEKAR Avanti Arvind, YOO Jesse I, O''BERRY Anthony Ray, IRWIN-PACK Kim Rees
Format Patent
LanguageEnglish
Spanish
Published 26.10.2021
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:Compositions and methods are described for the delivery of therapeutic products (such as therapeutic proteins (for example, antibodies), therapeutic RNAs (for example, shRNAs, siRNAs, and miRNAs), and therapeutic aptamers) to the retina/vitreal humour in the eyes of human subjects to treat pathologies of the eye, involving, for example, recombinant viral vectors such as recombinant adeno-associated virus (rAAV) vectors. Composiciones y métodos para la administración de productos terapéuticos (tales como proteínas terapéuticas (anticuerpos), ARN terapéuticos (shARN, siARN y miARN) y aptámeros terapéuticos) a la retina/humor vítreo en los ojos de sujetos humanos para tratar patologías oculares, que implican vectores virales recombinantes tales como vectores de virus adenoasociado recombinante (rAAV).
Bibliography:Application Number: MX2021011889